Navigation Links
NEBA Health earns patent for integration of NEBA biomarker with clinician's ADHD evaluation
Date:8/15/2013

BOULDER, Colo., Aug. 15, 2013 /PRNewswire/ -- NEBA Health, LLC announces today that Dr. Steven M. Snyder, Research and Development Vice President, has earned US Patent 8,509,884.  The patent protects a key aspect of the NEBA system:  integrating the biomarker with a clinician's workup for ADHD.  "NEBA is not a standalone diagnostic," said Dr. Snyder.  "After the clinician's ADHD evaluation, NEBA helps them determine if the symptoms are due to ADHD or if further testing is warranted."  

"Integrating the NEBA biomarker with a clinician's initial diagnostic impression can bring a clinician's diagnosis more in line with that of multidisciplinary team," said Dr. Snyder.  Research supports that compared to a clinician alone, a multidisciplinary team is better able to determine if ADHD-like symptoms are accounted for by another condition. 

In order to diagnose ADHD, a clinician not only observes criteria regarding behavioral symptoms and impairment, but also must determine whether symptoms would be better accounted for by another condition.  Because ADHD shares symptoms with other disorders, the diagnosis may be difficult.  According to the US Center for Disease Control and Prevention (CDC), 9.5% of all children and adolescents have an ADHD diagnosis.  The ADHD diagnosis rate is increasing.  CDC states that rates of ADHD diagnosis increased an average of 3% per year from 1997 to 2006 and an average of 5.5% per year from 2003 to 2007.

"In their ADHD evaluation, clinicians may be challenged in the current medical environment to determine the primary diagnosis when overlapping symptoms are present," said Howard Merry, President of NEBA Health.  "We are delighted that the USPTO has awarded Dr. Snyder the patent.  It covers NEBA's core technology, and it's another validation point for the 7 years we spent developing and validating NEBA." 

About NEBA Health

NEBA Health has developed the first FDA approved medical device based on brain waves to help assess ADHD.  The device, NEBA, is cleared in the USA (K112711), CE marked, and Health Canada licensed.  To our knowledge, the NEBA FDA validation study is the largest ADHD diagnostic study of this nature ever conducted (275 subjects at 13 clinical sites).  We have ongoing work in ADHD, depression, and dementia.  Our technologies are NIEAAs (Neuropsychiatric Interpretive EEG-based Assessment Aids).  NEBA Health is privately held.


'/>"/>
SOURCE NEBA Health, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First students at new College of Pharmacy to begin classes next week at UNT Health Science Center
2. mHealth Identified as Critical Strategy in Medication Adherence Programs
3. iSALUS Healthcare Expands Revenue Cycle Management Services with Billnet Solutions
4. Natus Neurology Incorporated Receives 510(k) & Health Canada Clearance And Launches New Electrodiagnostic System In U.S. & Canada
5. Millennium HealthCare Inc. Featured in Forbes
6. Wolters Kluwer Health Launches Nursing Drug Handbook Specialty Apps
7. PinnacleHealth, Meridian Health Select Perioperative IT from Surgical Information Systems
8. Hospira to Present at the Morgan Stanley Global Healthcare Conference
9. Chinas Strong Economic Growth and Healthcare Investments Generate Success for CPhI
10. Endo and Metamark Announce Sale of HealthTronics Laboratory Solutions
11. Real Time Location Systems (RTLS) Market in Healthcare Industry 2011 - 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):